Welcome to our dedicated page for Verrica Pharmaceuticals news (Ticker: VRCA), a resource for investors and traders seeking the latest updates and insights on Verrica Pharmaceuticals stock.
Verrica Pharmaceuticals Inc. reports news on its dermatology therapeutics business, including commercialization of YCANTH (VP-102) for molluscum contagiosum and development of cantharidin-based therapy for common warts. Company updates also cover financial results, corporate presentations, commercial leadership and international commercialization activity.
Verrica’s pipeline news centers on VP-315 (ruxotemitide), an oncolytic peptide licensed for dermatologic oncology indications. Recurring disclosures include clinical data presentations in basal cell carcinoma, development plans for non-melanoma skin cancers and collaboration activity tied to YCANTH and its dermatology portfolio.
Verrica Pharmaceuticals (Nasdaq: VRCA) reported dosing the first U.S. patient in COVE-3, the second pivotal Phase 3 trial of YCANTH (VP-102) for common warts. Torii Pharmaceutical recently dosed the first Japanese patient. A prior Phase 2 trial showed 51% complete clearance at Day 84. Torii will fund the first $40 million of Phase 3 costs, about 90% of the current budget, under a 50/50 cost-sharing agreement.
Verrica Pharmaceuticals (NASDAQ: VRCA) announced that President and CEO Jayson Rieger will present at the Jefferies Global Healthcare Conference in New York.
The presentation is scheduled for Thursday, June 4, 2026, at 11:05 a.m. ET, with a live and replay webcast available via Verrica’s investor website.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced that President and CEO Jayson Rieger, PhD, MBA, will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on May 19, 2026, at 1:30 p.m. ET.
A live webcast and 90-day replay will be available via Verrica’s investor relations website.
Verrica Pharmaceuticals (Nasdaq: VRCA) reported Q1 2026 revenue of $5.0 million, including U.S. YCANTH net product revenue of $4.3 million, up 16.2% sequentially and 25.4% year-over-year. Dispensed YCANTH applicator units reached 15,302, up 12.1% sequentially and 51.3% year-over-year.
YCANTH surpassed 100,000 total dispensed units since launch and was commercially launched in Japan by partner Torii. Verrica reported a GAAP net loss of $9.7 million and continues Phase 3 programs in common warts and development of VP-315 for basal cell carcinoma.
Verrica Pharmaceuticals (Nasdaq: VRCA) will present Phase 2 data on VP-315 (ruxotemitide) showing reductions in untreated basal cell carcinoma (BCC) lesions consistent with a potential abscopal effect. In 9 subjects, 14 non-treated lesions showed a 67% overall size reduction and 21% complete histologic clearance (3/14).
The poster will be presented May 15, 2026 at the SID Annual Meeting and reports an average 86% overall tumor-size reduction referenced for treated patients.
Verrica Pharmaceuticals (Nasdaq: VRCA) will report first-quarter 2026 financial results and provide a corporate update on Tuesday, May 12, 2026 at 4:30 p.m. ET.
The company will host a conference call and live webcast; domestic and international dial-in numbers and a conference ID (VERRICA) are provided. A webcast replay will be archived on Verrica's investor website for 90 days.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced acceptance of a late-breaking abstract reporting Phase 2 exploratory data for VP-315, its oncolytic peptide for basal cell carcinoma, showing a potential abscopal effect in untreated non-target BCC tumors.
The data will be presented at the 2026 Society for Investigative Dermatology Annual Meeting, May 13-16, with the poster session on May 15, 2026 (4:30 pm–6:00 pm) in Chicago (Hilton Chicago, Salons B,C,D).
Verrica Pharmaceuticals (Nasdaq: VRCA) announced that President and CEO Jayson Rieger, PhD, MBA, will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026 at 3:00pm ET.
A live webcast will be available via Verrica's investor site and a replay will be posted and available for 90 days.
Verrica Pharmaceuticals (Nasdaq: VRCA) reported full-year 2025 results and operational updates on March 11, 2026. YCANTH net revenue grew 130% to $15.3M and dispensed applicator units rose 99% to 51,296. Total 2025 revenue was $35.6M vs. $7.6M in 2024.
The company cut SG&A by over 40%, has no outstanding debt after a $50M private placement, and expects cash runway into Q1 2027. Clinical progress: first patient dosed in Phase 3 common warts program and VP-315 advances toward Phase 3 for basal cell carcinoma with supportive abscopal data.
Verrica Pharmaceuticals (Nasdaq: VRCA) will report fourth quarter and full year 2025 financial results and provide a corporate update on March 11, 2026.
The company will host a conference call and live webcast at 8:30 a.m. ET; dial-in details, conference ID VERRICA, and a 90-day webcast replay are available on the company website.